Loading...
  • 2018
  • SAN DIEGO - Treatment with luspatercept, a first-in-class erythroid maturation agent, in patients with lower-risk myelodysplastic syndrome with ring sideroblasts, led to a significant reduction in transfusion burden and was well-tolerated by patients, according to results of a study presented in the plenary session at the 2018 American Society of Hematology Annual Meeting in San Diego, California. (cancertherapyadvisor.com)
  • According to the study " Myelodysplastic Syndrome - Pipeline Review, H1 2018 ", global myelodysplastic syndrome market will witness a growth at a moderate pace due to insufficient medical needs, increasing public awareness, and increase in the aged population. (researchnewstoday.com)
  • Onconova Therapeutics, Inc. (ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes, today announced that the Company will release its third quarter 2018 financial results on Tuesday, November 13, 2018, before the market opens. (yahoo.com)
  • Onconova Therapeutics, Inc. (ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), today announced that Dr. Ramesh Kumar, CEO, will be meeting with potential Investors and Business Development partners at the 2018 Bio-Europe International Partnering Conference in Copenhagen. (yahoo.com)
  • clinical
  • The latest series of review articles in the Blood Journal provides a comprehensive overview of the current landscape of myelodysplastic syndromes (MDS), highlighting recent advances in biological and clinical science. (bethematchclinical.org)
  • Clinical effect of point mutations in myelodysplastic syndromes. (informdx.com)
  • The pipeline guide also provides the emerging players involved in therapeutic development for myelodysplastic syndrome, list of therapeutics under development or rejected in various companies or universities or institutes, clinical trial registries, conferences, SEC filings, investor presentations and industry-specific third party sources. (researchnewstoday.com)
  • This is a randomized, double-blind, clinical trial for men and women with high risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMMoL). (cornellleukemia.com)
  • The application seeking approval for the additional indication of NESP ® has been filed based on a clinical trial conducted in Japan and Korea, as well as foreign clinical data which have provided new confirmation of its safety and efficacy for anemia with myelodysplastic syndrome. (kyowa-kirin.com)
  • Información confiable y compasiva para personas con cáncer, sus familiares y sus cuidadores, de parte de expertos de la American Society of Clinical Oncology (la Sociedad Estadounidense de Oncología Clínica, ASCO por sus siglas en inglés), la voz de los médicos del cáncer y los profesionales oncológicos del mundo. (cancer.net)
  • Azacitidine
  • The purpose of this study is to to compare the safety and efficacy (how well it works) of azacitidine plus an investigational drug (birinapant) versus azacitidine plus a placebo (an inactive substance), in patients with higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMMoL). (cornellleukemia.com)
  • cytogenetics
  • Various diagnostic tools and techniques are available in the global market such as blood count, peripheral blood smear test, microscopic exams, cytochemistry, flow cytometry, immunotherapy, cytogenetics, FISH, and PCR that help in detecting myelodysplastic syndrome. (researchnewstoday.com)
  • Anemia
  • Anemia is the most frequent peripheral cytopenia observed in myelodysplastic syndromes (MDS) and has been recognized among the most important factors affecting the outcome of patients with MDS. (unipv.it)
  • Tokyo, Japan, March 31, 2014 --- Kyowa Hakko Kirin Co, Ltd. (Tokyo: 4151, President and CEO: Nobuo Hanai, "Kyowa Hakko Kirin") today announced that it has filed an application to Japan's Ministry of Health, Labour and Welfare (MHLW) seeking approval for additional indication of NESP ® Injection Plastic Syringe (NESP ® ) for anemia with myelodysplastic syndrome. (kyowa-kirin.com)
  • Chelation Therapy
  • Maha A. Badawi, Linda M. Vickars, Jocelyn M. Chase, and Heather A. Leitch, "Red Blood Cell Transfusion Independence Following the Initiation of Iron Chelation Therapy in Myelodysplastic Syndrome," Advances in Hematology , vol. 2010, Article ID 164045, 5 pages, 2010. (hindawi.com)
  • cancer
  • Myelodysplastic syndromes that occur in response to cancer treatments, such as chemotherapy and radiation, or in response to chemical exposure are called secondary myelodysplastic syndromes. (fortishealthcare.com)
  • Your risk of myelodysplastic syndromes is increased if you received chemotherapy or radiation therapy, both of which are commonly used to treat cancer. (fortishealthcare.com)
  • There is a high number of uncaptured cases with myelodysplastic syndromes (MDS) by population-based cancer registries. (ovid.com)
  • According to a report published in 2015 by American Cancer Society, myelodysplastic syndromes occurs at the rate of 4.8 cases per 100,000 people, which counts up to 13,000 new cases of MDS in the U.S. every year. (coherentmarketinsights.com)
  • TAMPA, Fla. (Nov. 4, 2014) - Moffitt Cancer Center and M2Gen ® have been awarded a contract from the National Institutes of Health's National Heart, Lung, and Blood Institute (NHLBI) to serve as the Central Laboratory and Biorepository for The National Myelodysplastic Syndromes Natural History Study (The National MDS Study). (tampabaynewswire.com)
  • Available at: https://www.cancer.org/cancer/myelodysplastic-syndrome/causes-risks-prevention/prevention.html. (cvs.com)
  • According to the National Institutes of Health, the frequency and incidence of myelodysplastic syndromes (MDS) is increasing in the US population and is influenced by factors such as advancing age, the use of cytotoxic and mutagenic therapies for cancer, and greater exposure to environmental toxins. (informdx.com)
  • Onconova Therapeutics, Inc. (ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), today announced that Mr. Abraham "Avi" Oler has joined Onconova's management team as Vice President, Corporate Development and General Counsel. (yahoo.com)
  • Onconova Therapeutics, Inc. (ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), today announced the appointment of Dr. Richard "Ric" Woodman as Chief Medical Officer and Senior Vice President of Research & Development. (yahoo.com)